Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US for IgAN, a disease characterised by the accumulation of antibodies in the ...
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...
Biogen Pharmachem Industries Ltd share price was down by -1.02% from the previous closing price of ₹0.98. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...
Leqembi — sold through a partnership between Eisai and Cambridge-based Biogen Inc. — is one of the first medications approved that promises to slow the speed at which Alzheimer’s erases a ...
Liquidia Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat ...
Die Aktie von Lufthansa gehört am Mittwochnachmittag zu den Verlierern des Tages. Die Lufthansa-Aktie notierte im XETRA-Handel zuletzt mit Abschlägen von 3,0 Prozent bei 7,22 EUR. Die Aktionäre ...
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und . Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOGEN INC finden Sie auf Wallstreet Online.
Kisunla, along with two approved Alzheimer’s therapies from partners Biogen and Eisai, is part of a class of drugs that can also cause side effects like swelling and small-scale bleeding in the brain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback